Holy Name Press Releases

Holy Name Performs First Ultrasound Renal Denervation Procedure in N.J.

Nationwide more than 54 million adults have high blood pressure and this provides a new, FDA approved therapy for hypertensive patients.

April 5, 2024

Holy Name is proud to announce the successful completion of the first ultrasound renal denervation procedure in New Jersey, which is designed to significantly lower a patient’s blood pressure and has been shown to be safe and effective across three randomized controlled clinical trials.

The procedure was performed by Jaffar Raza, MD, FACC, FSCAI, an interventional cardiologist at Holy Name using the Paradise® Ultrasound Renal Denervation (RDN) system. The procedure is FDA-approved and offers a safe and effective option for patients who have not responded to traditional blood pressure treatment options, including lifestyle changes and medications. Patients often find it challenging to tolerate medications due to side effects, and adhering to daily medication regimens can be burdensome for many, with patients missing doses or skipping their medications altogether.

Hypertensive patients that remain “uncontrolled,” meaning they have blood pressure outside the normal range, are at an increased risk for cardiovascular diseases, such as heart attack and heart failure, stroke, kidney disease, and cognitive issues.

"This is a significant milestone for Holy Name and our patients," said Dr. Raza. “We are committed to offering the latest and most effective treatments to our patients, and the introduction of ultrasound renal denervation is a testament to our dedication to improving health outcomes in our community."

The procedure is minimally invasive and may be performed in an outpatient setting, allowing most patients return home the same day.

To learn more about the procedure or to request a consultation with Dr. Raza, contact him at (201) 991-8565.